Insights On CONTRACT PHARMA MANUFACTURING

  1. Execution Matters: Why The Right CDMO Partner Defines Success 8/6/2026

    When evaluating development partners, execution matters. Strong processes, communication, and accountability can significantly impact timelines, costs, and outcomes.

  2. Thermo Fisher Scientific Capabilities Update July 2026: Fill/Finish 8/6/2026

    When working with high-value biologics, ADCs, and personalized medicines, material utilization decisions made before GMP manufacturing can make or break your program yield. Learn how early choices matter.

  3. How Baby KJ Is Ushering In A New Era In CRISPR Medicine 8/5/2026

    A personalized gene-editing therapy was developed in months, showcasing how collaboration, manufacturing innovation, and regulatory alignment can accelerate treatments for rare diseases.

  4. Why Analytical Characterization Now Drives Biosimilar Development 8/3/2026

    Updated FDA guidance establishes that biosimilar sponsors should generate comprehensive, comparative physicochemical and functional data early to establish more effective development strategies.

  5. Expand Trial Footprints Without Expanding Cryopreservation Risk 8/3/2026

    Transitioning from fresh to frozen starting material stabilizes cell therapy inputs, but isolated workflows introduce risk. Integrated logistics safeguard quality as trial footprints expand.

  6. When Local Variation Becomes Global Risk In Phase III 8/3/2026

    Late-stage therapy trials demand strict execution. Learn how local handling variations escalate into global risks and how early standardization safeguards therapeutic integrity and compliance.

  7. Regulatory Readiness Is Built Early 8/3/2026

    Building regulatory readiness early in cell and gene therapy development protects product integrity, prevents costly delays, and secures long-term program viability.

  8. SK Pharmteco Capabilities Update July 2026: Gene Therapy 8/3/2026

    Adaptive viral vector platforms pair scalable manufacturing with targeted purification. Customizing workflows ensures high vector purity and cost efficiency, accelerating clinical development.

  9. Andelyn Capabilities Update July 2026: Gene Therapy 8/3/2026

    Modular vector platforms blend custom transfection with gentle purification. Optimized TFF plus precise chromatography yield high vector recovery across diverse cell and gene therapy applications.

  10. KBI BioPharma Capabilities Update July 2026: Large Molecule 8/3/2026

    Combining targeted transposon tech with stable bulk pool generation accelerates cell line development, enabling early material production and fast-tracking candidate selection for clinical entry.